Diroximel Fumarate
Overview
Diroximel Fumarate is an oral medication used to treat relapsing forms of multiple sclerosis (MS) in adults. It is a prodrug that is rapidly converted into monomethyl fumarate, which exerts anti-inflammatory effects.
API suppliers (6)
Suppliers of Diroximel Fumarate evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 5 of 6 suppliers.
5 of 6 hold a GMP certificate on record in the EU or UK registers
- TAPI NL BVNetherlands1 active DMF
- ALIVUS LIFE SCIENCES LTDIndia1 active DMF GMP on record
- Intas Pharmaceuticals Ltd.India1 active DMF GMP on record
- Zydus Lifesciences LimitedIndia1 active DMF GMP on record
- HONOUR LAB LTDIndia1 active DMF GMP on record
- DR REDDYS LABORATORIES LTD1 active DMF GMP on record
Therapeutic areas
Do you supply Diroximel Fumarate? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.